ClinicalTrials.gg

Program

REGN17372

A development code. Also written as “REGN17372+Linvoseltamab”.

Its studies are mostly in Multiple Myeloma, led by Regeneron Pharmaceuticals.

Furthest: phase 2, since Mar 2, 20261 company-led study, 1 open or runningNext primary completion: Sep 30, 2033 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Regeneron Pharmaceuticals11 open or runningphase 2since Mar 2, 2026Mar 2, 2026Sep 30, 2033phase 2 · NCT07455851

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 2, 2026First study: phase 2 study in Multiple MyelomaFirst studyNCT07455851 · 150 planned · Australia, Greece

Ahead

  1. Sep 30, 2033Primary completion: phase 2 study in Multiple MyelomaNCT07455851

TargetBeta

“A FIH Phase 1/2 Study to Assess Safety, Tolerability, and Preliminary Anti-Tumor Activity of REGN17372, an Anti-GPRC5D x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody, in Combination With Linvoseltamab, an Anti-BCMA x Anti-CD3 Bispecific Monoclonal Antibody, in Participants With Relapsed…”study text, by rule · the study

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07455851Multiple Myeloma · Australia, Greece2RecruitingSep 30, 2033150

How it is read

Names in the registry

  • “REGN17372+Linvoseltamab”, 1 entry

Codes read as this program: REGN17372.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.